Key result
This editorial summarizes multiple studies on cardiovascular prevention, including a 9.7% global prevalence of lower extremity artery disease and a 1.51-fold increased risk of female sexual dysfunction in women with cardiovascular conditions.
Answers are grounded in this paper and cite their sources.
Highlights cardiovascular risk conditions and secondary prevention strategies across multiple populations, suggesting key targets for clinical intervention.
This issue of the European Journal of Preventive Cardiology focuses on the prevention of cardiovascular disease in clinical practice, from epidemiology to secondary prevention and intervention in atherosclerosis. Hereditary transthyretin amyloidosis (ATTRv) is one of the leading aetiologies of systemic amyloidosis with >135 mutations described and a broad spectrum of clinical manifestations. Here, a retrospective study offers a wide and comprehensive overview of ATTRv from the point of view of a tertiary referral centre in Italy. A total of 325 consecutive patients, harbouring a pathogenic mutation in the TTR gene, were followed up for 51 months: 106 were asymptomatic carriers, 49 presented with a cardiac phenotype, 49 had a neurological phenotype, and 121 had a mixed phenotype. Twenty-two different mutations were found; 111 patients (38.3%) died and 9 (11.5%) of the 78 asymptomatic carriers developed ATTRv. Carriers had a prognosis comparable with healthy population, while no significant differences were seen among the three phenotypes adjusted by age. Age at diagnosis, New York Heart Association class III, left ventricular ejection fraction, modified polyneuropathy disability score IV, and disease-modifying therapy were independently associated with survival.1 Along with coronary arteries and cerebrovascular diseases, lower extremity artery disease (LEAD) is one of the most frequent presentations of atherosclerosis. It encompasses for all arteries affected by atherosclerosis, from the termination of the aorta to the feet arteries. A systematic literature review in the general population showed that LEAD global prevalence in adults, mostly ≥40 years, was estimated at 9.7%, higher in women (10.2%) than in men (8.8%), increasing sharply with age, with the highest prevalence in South–Central Asia (14.5%). The significant associations between LEAD and common risk factors (smoking, diabetes, hypertension, obesity, and hypercholesterolaemia) confirmed the role of preventive interventions.2 Sexual dysfunction refers to any problem that arises during the sexual response cycle and sexual intercourse and negatively impacts sexual behaviour. Female sexual dysfunction (FSD) is a frequent condition with a prevalence of ∼43% among women in the USA. The development of FSD is associated with various factors, including hormonal dysfunction, nervous disorder, vascular disorder, medications, psychological factors, and sociocultural factors. A systematic analysis encompassing 45 cross-sectional and 11 longitudinal studies with 148 946 women reported that patients with cardiovascular conditions had a 1.51-fold increased risk of FSD: particularly, hypertension, stroke, and myocardial infarction were significantly associated with FSD.3 These findings indicate that more attention should be paid to women’s sexual health, particularly in the presence of cardiovascular risk factors. Alcohol consumption is a well-known risk factor for causing disability and death in both men and women across all age groups, particularly when consumed in excess. Among 6557 patients hospitalized for acute coronary syndrome (ACS) at four Swiss centres followed over 12 months, episodes of binge drinking, even less than once per month, but not regular weekly alcohol consumption were associated with the risk of major adverse cardiovascular events.4 It seems that not the frequency but rather the quantity of alcohol intake in a binge drinking episode that is associated with worse prognosis. However, there is still insufficient evidence to provide strong message because of the potential presence of confounders in this cohort of subjects. Despite scientific evidence on the effectiveness, safety, and benefits of the vaccines and recommendations to vaccinate elderly patients and those with risk factors, vaccination rates remain sub-optimal in this population. Doubts about vaccine necessity or efficacy and concerns about possible adverse events in patients and physicians refer to delayed acceptance. Vaccination campaigns targeting increasing professional recommendations and public perceptions should be implemented in the coming years. Awareness of vaccinations should be improved in cardiologists and patients with cardiovascular disease.5 Most studies of treatment adherence after ACS are based on prescribed drugs and lack long-term follow-up or consecutive data on risk factor control. A real-world retrospective observational study involved 3765 elderly patients (mean age 75 years, 40% women) for up to 8 years after incident ACS. Only a low proportion had satisfied risk factor control (66% blood pressure and 56% cholesterol), but most worrying was the reported lower percentage of regular assessment of blood pressure (62%) and low-density lipoprotein cholesterol (LDL-C, 28%). Moreover, it was confirmed that higher levels of LDL-C were associated with a higher risk of recurrent coronary event and death.6 Patients with chronic kidney disease (CKD) are at an increased risk of developing heart failure (HF). The American Heart Association recently released a new metric, Life’s Essential 8 (LE8), for health promotion. The relationship between cardiovascular health and the risk of HF in patients with CKD was investigated in 16 190 patients (mean age 55.9 years), free of cardiovascular disease at recruitment from the Kailuan Study, in China. Patients with CKD who had better cardiovascular health, as indicated by higher LE8 scores, had a significantly lower risk of HF. A stronger association between better LE8 score and lower risk of HF among CKD patients aged ≤65 years was observed, compared with their older counterparts.7 The risk of developing HF after ACS is high. Coronary risk factors and cardiac and renal function have been reported as risk factors for developing HF. But also frailty, age, sedentary habit, and low exercise capacity are all well-known risk factors for HF and mortality. Here, in a large population of patients with ACS without a prior HF or complications of HF during hospitalization, higher skeletal muscle strength was associated with a lower risk of developing HF after ACS. The results of study suggest not only the benefit of assessing skeletal muscle strength in addition to traditional risk factors but also the benefit of exercise training after ACS.8 Sodium–glucose co-transporter-2 (SGLT2) inhibitors, originally developed as and still recommended as major glucose-lowering agents in patients with diabetes mellitus, have been proven to have cardiac and renal benefits. However, here, a systemic review and meta-analysis of the current literature are showing that SGLT2 inhibitors did not decrease the risk of atrial fibrillation (AF) occurrence in patients with cardiometabolic diseases or risk factors, regardless of follow-up duration, type or dose of the drug, or the patient population.9 Familial hypercholesterolaemia (FH) patients are subjected to a high lifetime exposure to LDL-C, despite the use of lipid-lowering therapy (LLT). Familial hypercholesterolaemia patients, divided into a subgroup of early treated (LLT initiated <25 years) and late treated (LLT initiated ≥25 years) patients, and an age- and sex-matched unaffected control group, underwent coronary computed tomography angiography (CCTA) with artificial intelligence–guided analysis. Early treated patients had a modestly lower cumulative LDL-C exposure compared with late treated FH patients (P 0.045), without significant difference in coronary atherosclerosis. Familial hypercholesterolaemia patients with above-median cumulative LDL-C exposure had significantly higher plaque prevalence (P = 0.001) compared with patients with below-median exposure. Thus, genetically confirmed FH patients have a higher coronary plaque burden than those without FH, with every 75 mmol/L ∗ years increase in lifetime cumulative LDL-C exposure resulting in a two-fold increase in total plaque volume. Early and potent LDL-C–lowering treatments are crucial for FH patients to prevent future cardiovascular diseases.10 Lipoprotein(a) [Lp(a)] has been proposed as a marker of as well as genetically determined causal risk factor for cardiovascular disease including coronary heart disease, peripheral arterial disease, ischaemic stroke, and calcific aortic valve stenosis. For example, the non-interventional, cross-sectional LipidCardio Study, which included 975 patients aged ≥21 years, reported an association between Lp(a) and coronary artery disease severity.11 However, in clinical practice, widespread assessment of Lp(a) is still lacking despite several guideline recommendations to measure Lp(a) at least once in a lifetime in all adults to identify those at high or very high risk due to elevated levels. There is lack of specific and potent Lp(a)-lowering drugs, but clinical trials are currently underway. Here, an overview12 of key findings from observational and genetic Lp(a) studies, highlighting the main challenges in observational Lp(a) studies, is presented, which proposes a minimum set of requirements to enhance the quality and harmonize the collection of Lp(a)-related data.
No takes yet. Share an insight, caveat, or question.
Guida et al. (2024) conducted an editorial in Cardiovascular disease prevention and risk conditions. This editorial summarizes multiple studies on cardiovascular prevention, including a 9.7% global prevalence of lower extremity artery disease and a 1.51-fold increased risk of female sexual dysfunction in women with cardiovascular conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: